Project Grant R41CA189600

Federal Grant Award Summary Vortex Therapeutics Inc. received a $1.1M Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective September 12, 2025, through August 31, 2027. The award supports the development of MYCI606, a novel small molecule inhibitor targeting MYC proteins (C-MYC, N-MYC, and L-MYC) for cancer therapy. MYC proteins are oncogenic drivers implicated in approximately 70% of all human cancers and are particularly...

This $683,472 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the University of Cincinnati to develop a novel targeted therapy for acute myeloid leukemia (AML). The key objectives are to therapeutically target the DHODH enzyme to induce AML cell differentiation, activate the immune system, and induce ferroptosis-mediated cell death. This approach aims to better differentiate AML cells from normal hematopoietic stem cells and enhance...

The National Cancer Institute, under the Cancer Biology Research Federal Grant Program (CFDA 93.396), awarded a $680,594 Project Grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct research on the novel regulation and functions of the TEAD-VGLL transcription factor complex. The key objectives of the 5-year project include: (1) characterizing the structure and functions of the TEAD-VGLL3 complex, (2) investigating TEAD-VGLL3's role in...

Federal Grant Award Summary Myosin Therapeutics Inc. received a $249,417 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective September 1, 2025, through August 31, 2026. The award funds the development of a drug product to support a Phase 0/1B dose escalation clinical trial of MT-125, a novel dual inhibitor of non-muscle myosin II (NMIIA and IIB), in patients with recurrent high-grade gliomas, particularly glioblastoma (GBM). MT-125...

The Department of the Army Medical Command awarded a $694,200 Project Grant to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) to support research developing a novel therapeutic target in XP11.2 translocation renal cell carcinoma. The grant was awarded on July 1, 2022 under the Military Medical Research and Development program (CFDA 12.420), with a completion date of June 30, 2025. Through this funding, Dfci will conduct research to investigate medical solutions for renal cell...

This $476,999 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports the Mayo Clinic's research on targeting the AXL receptor tyrosine kinase with a humanized anti-AXL monoclonal antibody as a novel therapy for ovarian cancer. The 4-year project aims to develop and evaluate this antibody-based treatment for ovarian cancer. As a leading non-profit academic medical center, Mayo Clinic leverages its expertise in...

The Department of the Army Medical Command awarded a $1,039,740 project grant to Dana-Farber Cancer Institute, Inc. (doing business as Dfci) to support research titled "NOVEL SYNERGISTIC ATR INHIBITOR COMBINATIONS FOR OVARIAN CANCER THERAPY." The period of performance is from August 1, 2021 to July 31, 2025. This project grant was awarded under the Military Medical Research and Development program (CFDA 12.420). This program supports basic, applied, and advanced biomedical research...

This $396,061 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to assess the efficacy of a novel class of hypoxia-inducible factor (HIF) inhibitors as a potential treatment for renal cell carcinoma (RCC). The principal investigator has developed boron-based HIF inhibitors derived from the natural compound honokiol, which have demonstrated promising anti-angiogenic properties in vitro. This 2-year project aims to (1) determine...

Federal Grant Award Summary The National Cancer Institute awarded the Regents of the University of Michigan a $640,135 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025 through July 31, 2030. This award supports the development of next-generation menin inhibitors designed to overcome clinical resistance observed in acute myeloid leukemia (AML) patients undergoing menin inhibitor therapy. The research addresses the critical clinical problem of...

The National Cancer Institute (NCI) has awarded a $154,400 Project Grant (CFDA 93.396 Cancer Biology Research) to The Broad Institute, Inc. to support research on activating the SLFN12 RNase enzyme's cytotoxic effects against cancer cells. The research aims to determine whether SLFN12 dimerization can induce tRNA-Leu-TAA degradation and cancer cell death, independent of the PDE3A protein. Experiments will test if high SLFN12 expression alone can trigger this cytotoxic response, and whether a...